Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Carlos F. Fernandez-del Castillo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5975-7225; OpenAlex author ID A5019690020. Sources: OpenAlex.

Their work

Papers
73 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
217
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 3 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 6 papers · 2018: 8 papers · 2019: 3 papers · 2020: 14 papers · 2021: 3 papers · 2022: 7 papers · 2023: 5 papers · 2024: 6 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 73

  1. Pancreatic Cancer Screening and Early Detection: Where Are We Now? Co-author DOI 10.1148/rg.250146↗
  2. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  3. Operation Alone for Resectable Pancreatic Adenocarcinoma: Should We Operate if Multimodal Treatment Is Off the Table? Co-author DOI 10.1097/xcs.0000000000001464↗
  4. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  5. Common hepatic artery lymph node metastasis in pancreatic ductal adenocarcinoma: an analysis of actual survival. Last author DOI 10.1016/j.gassur.2024.02.018↗
  6. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.09.041↗
  7. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  8. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  9. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  10. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  11. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  12. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  13. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  14. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  15. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
  16. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  17. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  18. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  19. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  20. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  21. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  22. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Last author DOI 10.1097/sla.0000000000005433↗
  23. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  24. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  25. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  26. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy-Reply. Last author DOI 10.1001/jamasurg.2019.5091↗
  27. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  28. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Last author DOI 10.1016/j.pan.2019.10.007↗
  29. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  30. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  31. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  32. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  33. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  34. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08040-0↗
  35. Can Prognosis Be Modified in Pancreatic Cancer? First author DOI 10.1245/s10434-019-08052-w↗
  36. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… Last author DOI 10.1245/s10434-019-08084-2↗
  37. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗
  38. ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-020-08572-w↗
  39. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Co-author DOI 10.21873/anticanres.14355↗
  40. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-018-0196-2↗
  41. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  42. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Co-author DOI 10.1634/theoncologist.2018-0114↗
  43. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  44. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  45. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  46. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000336↗
  47. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  48. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Co-author DOI 10.1245/s10434-018-6764-3↗
  49. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Last author DOI 10.1245/s10434-018-6827-5↗
  50. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6832-8↗

Closest collaborators

The 25 strongest of 217 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith D. Lillemoe · 49 shared papers, 2012–2025 · strength 5.28
  2. Cristina Rosa Ferrone · 44 shared papers, 2012–2024 · strength 4.21
  3. Motaz Qadan · 29 shared papers, 2018–2025 · strength 4.11
  4. Theodore Sunki Hong · 29 shared papers, 2011–2024 · strength 2.36
  5. Andrew Louis Warshaw · 25 shared papers, 2012–2025 · strength 2.15
  6. Jennifer Yon-Li Wo · 22 shared papers, 2012–2024 · strength 1.92
  7. Mari A. Mino-Kenudson · 19 shared papers, 2011–2025 · strength 1.69
  8. David P. Ryan · 20 shared papers, 2011–2023 · strength 1.44
  9. Thomas P. Hank · 10 shared papers, 2020–2025 · strength 1.42
  10. David Tsai Ting · 12 shared papers, 2015–2025 · strength 1.24
  11. Lawrence Scott Blaszkowsky · 15 shared papers, 2011–2023 · strength 1.04
  12. Andrew Scott Liss · 10 shared papers, 2015–2025 · strength 0.92
  13. Vikram Deshpande · 13 shared papers, 2012–2022 · strength 0.91
  14. Jon Michael Harrison · 6 shared papers, 2020–2025 · strength 0.91
  15. Marta Sandini · 7 shared papers, 2018–2025 · strength 0.90
  16. Zhi Ven Fong · 7 shared papers, 2017–2024 · strength 0.84
  17. Kim C. Honselmann · 7 shared papers, 2017–2025 · strength 0.81
  18. Aparna R. Parikh · 5 shared papers, 2018–2023 · strength 0.62
  19. Louisa Bolm · 4 shared papers, 2020–2025 · strength 0.59
  20. Ulrich Friedrich Wellner · 5 shared papers, 2020–2024 · strength 0.57
  21. Fidel López‐Verdugo · 3 shared papers, 2023–2024 · strength 0.54
  22. Avinash R. Kambadakone · 3 shared papers, 2022–2026 · strength 0.54
  23. Cristina R. Ferrone · 6 shared papers, 2012–2025 · strength 0.54
  24. Natalie Petruch · 3 shared papers, 2022–2025 · strength 0.50
  25. Tobias Keck · 4 shared papers, 2020–2024 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.